TAKEDA PHARMACEUTICA

4502
End-of-day quote. End-of-day quote  - 09/18
3989JPY +0.99%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: March 2020 2021
Net sales1 3 291 2003 267 166
EBITDA1 684 0571 122 580
Operating profit (EBIT)1 100 400431 426
Operating Margin 3,05%13,2%
Pre-Tax Profit (EBT)1 -60 754279 033
Net income1 44 200174 772
Net margin 1,34%5,35%
EPS2 28,082,3
Dividend per Share2 180180
Last update 05/13/202009/02/2020
1 JPY in Million
2 JPY
Estimates
Finances - Leverage
Fiscal Period: March 2020 2021
Net Debt1 4 455 6903 934 784
Net Cash position1 --
Leverage (Debt / EBITDA) 6,51x3,51x
Free Cash Flow1 542 670748 897
ROE (Net Profit / Equities) 0,90%3,02%
Shareholders' equity1 4 911 1115 789 910
ROA (Net Profit / Asset) -0,46%1,23%
Assets1 -9 710 01814 267 142
Book Value Per Share2 3 0322 962
Cash Flow per Share2 403514
Capex1 127 082176 298
Capex / Sales 3,86%5,40%
Last update 05/13/202009/15/2020
1 JPY in Million
2 JPY
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 6 235 212 M JPY -
Entreprise Value (EV) 10 169 996 M JPY 9 480 176 M JPY
Valuation 2021e 2022e
P/E ratio (Price / EPS) 48,5x 14,7x
Capitalization / Revenue 1,91x 1,86x
EV / Revenue 3,11x 3,04x
EV / EBITDA 9,06x 8,13x
Yield (DPS / Price) 4,51% 4,51%
Price to book (Price / BVPS) 1,35x 1,32x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 13,2% 19,3%
Operating Leverage (Delta EBIT / Delta Sales) - 21,0x
Net Margin (Net Profit / Revenue) 5,35% 11,9%
ROA (Net Profit / Asset) 1,23% 3,99%
ROE (Net Profit / Equities) 3,02% 9,90%
Rate of Dividend 219% 66,4%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   5,40% 5,48%
Cash Flow / Sales 24,6% 27,3%
Capital Intensity (Assets / Sales) 4,37x 2,98x
Financial Leverage (Net Debt / EBITDA) 3,51x 2,59x
Price Earning Ratio
EPS & Dividend